Cargando…

Prescription amphetamines in people with opioid use disorder and co-occurring psychostimulant use disorder initiating buprenorphine: an analysis of treatment retention and overdose risk

BACKGROUND: Attention-deficit and hyperactivity disorder (ADHD) is frequently diagnosed in patients with substance use disorders (SUDs), including opioids. There remains concern about the safety and efficacy of prescription amphetamines (PAs) and their impact on effectiveness of opioid use disorder...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tardelli, Vitor, Xu, Kevin Y, Bisaga, Adam, Levin, Frances R, Fidalgo, Thiago M, Grucza, Richard A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Pharmacological Treatments
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387656/ https://www.ncbi.nlm.nih.gov/pubmed/37500184 http://dx.doi.org/10.1136/bmjment-2023-300728

Ejemplares similares

Co-occurring psychiatric disorders and disparities in buprenorphine utilization in opioid use disorder: An analysis of insurance claims
por: Xu, Kevin Y, et al.
Publicado: (2023)

The Therapeutic Potential of Amphetamine-like Psychostimulants
por: Pires, Bruno, et al.
Publicado: (2023)

Efficacy and safety of psychostimulants for amphetamine and methamphetamine use disorders: a systematic review and meta-analysis
por: Bhatt, Meha, et al.
Publicado: (2016)

Incorporating prescription psychostimulants into the continuum of care for people with stimulant use disorder in Canada
por: Palis, Heather, et al.
Publicado: (2023)

Cocaine and amphetamine-like psychostimulants: neurocircuitry and glutamate neuroplasticity
por: Kalivas, Peter W.
Publicado: (2007)

Dental management of patients with substance use disorder
por: Cuberos, Mara, et al.
Publicado: (2020)

Evidence base to support using prescribed psychostimulants to treat psychostimulant use disorder is limited
por: Bahji, Anees, et al.
Publicado: (2023)

Analysis of Stimulant Prescriptions and Drug-Related Poisoning Risk Among Persons Receiving Buprenorphine Treatment for Opioid Use Disorder
por: Mintz, Carrie M., et al.
Publicado: (2022)

Comparative Effectiveness Associated With Buprenorphine and Naltrexone in Opioid Use Disorder and Cooccurring Polysubstance Use
por: Xu, Kevin Y., et al.
Publicado: (2022)

Psychostimulants and Movement Disorders
por: Asser, Andres, et al.
Publicado: (2015)

Critical examination of incorporating prescription psychostimulants into the continuum of care for people with stimulant use disorder in Canada
por: Morin, Kristen A., et al.
Publicado: (2023)

Telemedicine Buprenorphine Initiation and Retention in Opioid Use Disorder Treatment for Medicaid Enrollees
por: Hammerslag, Lindsey R., et al.
Publicado: (2023)

Overdose death rates in Brazil: an ecological analysis by region
por: Tardelli, Vitor S., et al.
Publicado: (2023)

Overdose deaths involving non-BZD hypnotic/sedatives in the USA: Trends analyses
por: Tardelli, Vitor S., et al.
Publicado: (2022)

Cocaine- and Amphetamine-Regulated Transcript (CART) Peptide Plays Critical Role in Psychostimulant-Induced Depression
por: Meng, Qing, et al.
Publicado: (2018)

The SARS-Cov-2 threat in Cracolândia, an open-air drug use scene in Brazil
por: Arcadepani, Felipe B., et al.
Publicado: (2020)

The authors respond to letters on using prescribed psychostimulants to treat stimulant use disorder
por: Palis, Heather N., et al.
Publicado: (2023)

Attention-deficit hyperactivity disorder and use of psychostimulants among children in Turkey
por: Aras, Sahbal, et al.
Publicado: (2007)

Critical View on the Usage of Ribavirin in Already Existing Psychostimulant-Use Disorder
por: Petković, Branka, et al.
Publicado: (2020)

Evaluation of the Effectiveness of Buprenorphine-Naloxone on Opioid Overdose and Death among Insured Patients with Opioid Use Disorder in the United States
por: Sun, Tianyu, et al.
Publicado: (2022)

Overdose Deaths Involving Opioids, Cocaine, and Psychostimulants — United States, 2015–2016
por: Seth, Puja, et al.
Publicado: (2018)

Insulin degludec overdose in an adolescent with type 1 diabetes: proactive management including monitoring using the Freestyle Libre flash glucose monitoring system
por: Thompson, Harmony, et al.
Publicado: (2018)

Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naïve patients with spondyloarthritis
por: Lindström, Ulf, et al.
Publicado: (2019)

Pitolisant, a wake‐promoting agent devoid of psychostimulant properties: Preclinical comparison with amphetamine, modafinil, and solriamfetol
por: Krief, Stéphane, et al.
Publicado: (2021)

Use of and Retention on Video, Telephone, and In-Person Buprenorphine Treatment for Opioid Use Disorder During the COVID-19 Pandemic
por: Frost, Madeline C., et al.
Publicado: (2022)

Buprenorphine treatment retention and comorbidities among patients with opioid use disorder in a primary care setting
por: Sweeney, Mary M., et al.
Publicado: (2022)

Association of a Multimodal Educational Intervention for Primary Care Physicians With Prescriptions of Buprenorphine for Opioid Use Disorders
por: Clark, Brinton, et al.
Publicado: (2019)

Dysregulation of Acetylation Enzymes in Animal Models of Psychostimulant use Disorders: Evolving Stories
por: Cadet, Jean Lud
Publicado: (2016)

Psychostimulant Use Disorder, an Unmet Therapeutic Goal: Can Modafinil Narrow the Gap?
por: Hersey, Melinda, et al.
Publicado: (2021)

Association between recent overdose and chronic pain among individuals in treatment for opioid use disorder
por: Hartz, Sarah M., et al.
Publicado: (2022)

Buprenorphine‐naloxone, buprenorphine, and methadone throughout pregnancy in maternal opioid use disorder
por: Kanervo, Minna M., et al.
Publicado: (2022)

Association of Buprenorphine-Waivered Physician Supply With Buprenorphine Treatment Use and Prescription Opioid Use in Medicaid Enrollees
por: Wen, Hefei, et al.
Publicado: (2018)

Patterns of use and adverse events reported among persons who regularly inject buprenorphine: a systematic review
por: Bozinoff, Nikki, et al.
Publicado: (2022)

Association of Duration of Methadone or Buprenorphine Use During Pregnancy With Risk of Nonfatal Drug Overdose Among Pregnant Persons With Opioid Use Disorder in the US
por: Jarlenski, Marian, et al.
Publicado: (2022)

Buprenorphine/naloxone addiction in a pharmacist as a result of migraine self-treatment
por: Norton, Merrill, et al.
Publicado: (2016)

The Pharmacology of Buprenorphine Microinduction for Opioid Use Disorder
por: De Aquino, Joao P., et al.
Publicado: (2021)

Does illicit amphetamine seizures quantity associated with amphetamine use disorder related admissions in Saudi Arabia?
por: Ramadan, Majed, et al.
Publicado: (2023)

Correction: Patterns of use and adverse events reported among persons who regularly inject buprenorphine: a systematic review
por: Bozinoff, Nikki, et al.
Publicado: (2022)

Drug Overdose Deaths Involving Cocaine and Psychostimulants with Abuse Potential — United States, 2003–2017
por: Kariisa, Mbabazi, et al.
Publicado: (2019)

The role of the GABA system in amphetamine-type stimulant use disorders
por: Jiao, Dongliang, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_hjf167kiohujpcgj78en84k3jm